Thevis Mario, Krug Oliver, Geyer Hans, Walpurgis Katja, Baume Norbert, Thomas Andreas
Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
Anal Bioanal Chem. 2018 Mar;410(9):2275-2281. doi: 10.1007/s00216-018-0934-9. Epub 2018 Feb 14.
Analytical chemistry represents a central aspect of doping controls. Routine sports drug testing approaches are primarily designed to address the question whether a prohibited substance is present in a doping control sample and whether prohibited methods (for example, blood transfusion or sample manipulation) have been conducted by an athlete. As some athletes have availed themselves of the substantial breadth of research and development in the pharmaceutical arena, proactive and preventive measures are required such as the early implementation of new drug candidates and corresponding metabolites into routine doping control assays, even though these drug candidates are to date not approved for human use. Beyond this, analytical data are also cornerstones of investigations into atypical or adverse analytical findings, where the overall picture provides ample reason for follow-up studies. Such studies have been of most diverse nature, and tailored approaches have been required to probe hypotheses and scenarios reported by the involved parties concerning the plausibility and consistency of statements and (analytical) facts. In order to outline the variety of challenges that doping control laboratories are facing besides providing optimal detection capabilities and analytical comprehensiveness, selected case vignettes involving the follow-up of unconventional adverse analytical findings, urine sample manipulation, drug/food contamination issues, and unexpected biotransformation reactions are thematized.
分析化学是兴奋剂检测的核心内容。常规的运动药物检测方法主要用于解决两个问题:一是兴奋剂检测样本中是否存在违禁物质;二是运动员是否采用了违禁方法(如输血或样本操纵)。由于一些运动员利用了制药领域广泛的研发成果,因此需要采取积极主动的预防措施,比如在常规兴奋剂检测分析中尽早纳入新的候选药物及其相应代谢物,即便这些候选药物目前尚未获批用于人体。除此之外,分析数据也是对非典型或不良分析结果进行调查的基石,这些结果为后续研究提供了充分理由。此类研究性质多样,需要采用针对性方法来探究相关方报告的假设和情况,包括陈述和(分析)事实的合理性与一致性。为了概述兴奋剂检测实验室在提供最佳检测能力和分析全面性之外所面临的各种挑战,本文将对一些选定的案例进行专题讨论,这些案例涉及非常规不良分析结果的追踪、尿液样本操纵、药物/食物污染问题以及意外的生物转化反应。